Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd., a foreign private issuer, covers the month of August 2026. The report was filed on August 19, 2026, and primarily addresses a significant change in executive leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
- Executive Resignation: Mr. Eyal Rubin, Chief Financial Officer (CFO), resigned effective September 18, 2026.
- Reason for Departure: The resignation is not related to any disagreement with the Company regarding operations, policies, or practices.
- Interim Appointment: Mr. Oren Elmaliach, Director of Finance, has been appointed as interim CFO pending the selection of a permanent successor.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or specific risk factors beyond the standard disclosure of the leadership transition. The Company issued a press release titled "Nasus Pharma Announces Transition of Chief Financial Officer" on August 19, 2026, which is included as Exhibit 99.1.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (September 18, 2026).
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the full text of the press release (Exhibit 99.1) for any additional context on the transition plan.
- Verify that no undisclosed disagreements exist regarding the company's financial reporting or internal controls.